MV Mateos

2.5k total citations
37 papers, 750 citations indexed

About

MV Mateos is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, MV Mateos has authored 37 papers receiving a total of 750 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Hematology, 20 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in MV Mateos's work include Multiple Myeloma Research and Treatments (29 papers), Protein Degradation and Inhibitors (11 papers) and Cancer Treatment and Pharmacology (8 papers). MV Mateos is often cited by papers focused on Multiple Myeloma Research and Treatments (29 papers), Protein Degradation and Inhibitors (11 papers) and Cancer Treatment and Pharmacology (8 papers). MV Mateos collaborates with scholars based in Spain, United States and Germany. MV Mateos's co-authors include Jesús F. San Miguel, María‐Belén Vídriales, Marcos González, Dolores Caballero, Josè Antonio Pérez-Simón, Jesús María Hernández‐Rivas, Lourdes Vázquez, Mauricio Ocqueteau, Marı́a Dolores Caballero and Manuel Moro and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Leukemia.

In The Last Decade

MV Mateos

37 papers receiving 739 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
MV Mateos Spain	12	650	263	261	163	158	37	750
Marcello Rotta United States	13	631 1.0×	295 1.1×	314 1.2×	59 0.4×	168 1.1×	29	756
Cristina Bugarin Italy	13	273 0.4×	142 0.5×	153 0.6×	161 1.0×	197 1.2×	26	605
D Samson United Kingdom	14	549 0.8×	196 0.7×	213 0.8×	54 0.3×	169 1.1×	23	684
Xiao‐Su Zhao China	17	632 1.0×	143 0.5×	193 0.7×	227 1.4×	290 1.8×	45	852
Sharon Tindle United States	9	639 1.0×	312 1.2×	153 0.6×	41 0.3×	144 0.9×	19	742
C. Michel Zwaan Netherlands	17	689 1.1×	167 0.6×	349 1.3×	323 2.0×	73 0.5×	36	992
Tsuyoshi Takahashi Japan	9	408 0.6×	90 0.3×	91 0.3×	75 0.5×	205 1.3×	22	529
A. R. Zander Germany	8	332 0.5×	137 0.5×	102 0.4×	102 0.6×	186 1.2×	16	555
Leandro de Pádua Silva United States	9	572 0.9×	84 0.3×	226 0.9×	195 1.2×	120 0.8×	25	746
Susana Vives Spain	10	533 0.8×	209 0.8×	272 1.0×	231 1.4×	76 0.5×	37	791

Countries citing papers authored by MV Mateos

Since Specialization

Citations

This map shows the geographic impact of MV Mateos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by MV Mateos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites MV Mateos more than expected).

Fields of papers citing papers by MV Mateos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by MV Mateos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by MV Mateos. The network helps show where MV Mateos may publish in the future.

Co-authorship network of co-authors of MV Mateos

This figure shows the co-authorship network connecting the top 25 collaborators of MV Mateos. A scholar is included among the top collaborators of MV Mateos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with MV Mateos. MV Mateos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Quach, Hang, Olga Samoylova, Thierry Façon, et al.. (2020). CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES. Hematology Transfusion and Cell Therapy. 42. 253–254. 1 indexed citations

Hari, Parameswaran, MV Mateos, Rafat Abonour, et al.. (2017). Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes. Leukemia. 31(12). 2630–2641. 16 indexed citations

Usmani, Saad Z., Andrzej Jakubowiak, Ajai Chari, et al.. (2017). Split dosing of daratumumab (D) in a phase 1b study of D plus carfilzomib (K)-based regimens in patients (pts) with multiple myeloma (MM). Annals of Oncology. 28. v356–v356. 6 indexed citations

Lentzsch, Suzanne, Katja Weisel, MV Mateos, et al.. (2017). DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (CASTOR). Hematological Oncology. 35(S2). 388–389. 5 indexed citations

Ocio, Enrique M., Jatin J. Shah, Sundar Jagannath, et al.. (2016). Pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM): Randomized, phase 3 KEYNOTE-183 study. Annals of Oncology. 27. vi324–vi324. 2 indexed citations

Mateos, MV, Hilary Blacklock, Albert Oriol Rocafiguera, et al.. (2016). KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Annals of Oncology. 27. viii15–viii16. 1 indexed citations

Weisel, Katja, Antonio Palumbo, Asher Chanan‐Khan, et al.. (2016). Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR. Annals of Oncology. 27. vi313–vi313. 1 indexed citations

Usmani, Saad Z., Paula Rodríguez‐Otero, Manisha Bhutani, MV Mateos, & Jesús F. San Miguel. (2015). Defining and treating high-risk multiple myeloma. Leukemia. 29(11). 2119–2125. 46 indexed citations

González‐Calle, Verónica, Julio Dávila, Enrique M. Ocio, et al.. (2015). Immunoparesis Recovery as Predictor Marker of Progression After Autologous Stem Cell Transplantation in Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 15. S51–S51. 1 indexed citations

10.

Dimopoulos, Meletios Α., Xavier Leleu, Antonio Palumbo, et al.. (2014). Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 28(8). 1573–1585. 80 indexed citations

11.

Miguel, Jesús F. San & MV Mateos. (2013). Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation. PubMed. 2(S1). S21–S27. 5 indexed citations

12.

Vídriales, María‐Belén, Bruno Paiva, Carlos Fernández, et al.. (2012). Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica. 98(1). 79–86. 125 indexed citations

13.

Matarraz, Sergio, Bruno Paiva, María Díez‐Campelo, et al.. (2012). Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?. Haematologica. 97(10). 1608–1611. 12 indexed citations

14.

Palumbo, Antonio, Rudolf Schlag, Nuriet K. Khuageva, et al.. (2008). Prolonged therapy with bortezomib plus melphalan-prednisone (vmp) results in improved quality and duration of response in the phase iii vista study in previously untreated multiple myeloma (mm). 93. 83–83. 7 indexed citations

15.

Mateos, MV & Jesús F. San Miguel. (2007). Bortezomib in multiple myeloma. Best Practice & Research Clinical Haematology. 20(4). 701–715. 40 indexed citations

16.

Valcárcel, David, Rodrigo Martino, Dolores Caballero, et al.. (2003). Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplantation. 31(5). 387–392. 66 indexed citations

17.

Cañizo, M.C. del, Carmen Martı́nez, E. Condé, et al.. (2003). Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry. Bone Marrow Transplantation. 32(10). 987–992. 17 indexed citations

18.

López‐Pérez, Ricardo, Ramón García‐Sánz, David González, et al.. (2001). Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation. 28(7). 665–672. 14 indexed citations

19.

Pérez-Simón, Josè Antonio, Alejandro Martı́n, Dolores Caballero, et al.. (1999). Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation. 24(12). 1279–1283. 60 indexed citations

20.

Ciudad, Juana, Jesús F. San Miguel, M C López-Berges, et al.. (1998). Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia.. Journal of Clinical Oncology. 16(12). 3774–3781. 132 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact